Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
616 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hepatitis C - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hepatitis C - Pipeline Review, H2 2014', provides an overview of the Hepatitis C's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hepatitis C - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatitis C - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Hepatitis C Overview 8 Therapeutics Development 9 Hepatitis C - Therapeutics under Development by Companies 11 Hepatitis C - Therapeutics under Investigation by Universities/Institutes 21 Hepatitis C - Pipeline Products Glance 23 Hepatitis C - Products under Development by Companies 27 Hepatitis C - Products under Investigation by Universities/Institutes 42 Hepatitis C - Companies Involved in Therapeutics Development 45 Hepatitis C - Therapeutics Assessment 155 Drug Profiles 171 Hepatitis C - Recent Pipeline Updates 488 Hepatitis C - Dormant Projects 569 Hepatitis C - Discontinued Products 576 Hepatitis C - Product Development Milestones 578 Appendix 589
List of Tables Number of Products under Development for Hepatitis C, H2 2014 35 Number of Products under Development for Hepatitis C - Comparative Analysis, H2 2014 36 Number of Products under Development by Companies, H2 2014 38 Number of Products under Development by Companies, H2 2014 (Contd..1) 39 Number of Products under Development by Companies, H2 2014 (Contd..2) 40 Number of Products under Development by Companies, H2 2014 (Contd..3) 41 Number of Products under Development by Companies, H2 2014 (Contd..4) 42 Number of Products under Development by Companies, H2 2014 (Contd..5) 43 Number of Products under Development by Companies, H2 2014 (Contd..6) 44 Number of Products under Development by Companies, H2 2014 (Contd..7) 45 Number of Products under Development by Companies, H2 2014 (Contd..8) 46 Number of Products under Investigation by Universities/Institutes, H2 2014 47 Comparative Analysis by Late Stage Development, H2 2014 49 Comparative Analysis by Clinical Stage Development, H2 2014 50 Comparative Analysis by Early Stage Development, H2 2014 51 Comparative Analysis by Unknown Stage Development, H2 2014 52 Products under Development by Companies, H2 2014 53 Products under Development by Companies, H2 2014 (Contd..1) 54 Products under Development by Companies, H2 2014 (Contd..2) 55 Products under Development by Companies, H2 2014 (Contd..3) 56 Products under Development by Companies, H2 2014 (Contd..4) 57 Products under Development by Companies, H2 2014 (Contd..5) 58 Products under Development by Companies, H2 2014 (Contd..6) 59 Products under Development by Companies, H2 2014 (Contd..7) 60 Products under Development by Companies, H2 2014 (Contd..8) 61 Products under Development by Companies, H2 2014 (Contd..9) 62 Products under Development by Companies, H2 2014 (Contd..10) 63 Products under Development by Companies, H2 2014 (Contd..11) 64 Products under Development by Companies, H2 2014 (Contd..12) 65 Products under Development by Companies, H2 2014 (Contd..13) 66 Products under Development by Companies, H2 2014 (Contd..14) 67 Products under Investigation by Universities/Institutes, H2 2014 68 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 69 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 70 Hepatitis C - Pipeline by 3-V Biosciences, Inc., H2 2014 71 Hepatitis C - Pipeline by AbbVie Inc., H2 2014 72 Hepatitis C - Pipeline by Achillion Pharmaceuticals, Inc., H2 2014 73 Hepatitis C - Pipeline by Adaptimmune Limited, H2 2014 74 Hepatitis C - Pipeline by AiCuris GmbH & Co. KG, H2 2014 75 Hepatitis C - Pipeline by AIMM Therapeutics B.V., H2 2014 76 Hepatitis C - Pipeline by Akshaya Bio Inc., H2 2014 77 Hepatitis C - Pipeline by Alios BioPharma, Inc., H2 2014 78 Hepatitis C - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 79 Hepatitis C - Pipeline by Altor BioScience Corporation, H2 2014 80 Hepatitis C - Pipeline by Amarna Therapeutics B.V., H2 2014 81 Hepatitis C - Pipeline by American Gene Technologies International Inc., H2 2014 82 Hepatitis C - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 83 Hepatitis C - Pipeline by ARA Healthcare Pvt. Ltd., H2 2014 84 Hepatitis C - Pipeline by Ascendis Pharma A/S, H2 2014 85 Hepatitis C - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 86 Hepatitis C - Pipeline by Biogenomics Limited, H2 2014 87 Hepatitis C - Pipeline by BioLineRx, Ltd., H2 2014 88 Hepatitis C - Pipeline by Bionor Pharma ASA, H2 2014 89 Hepatitis C - Pipeline by Biotest AG, H2 2014 90 Hepatitis C - Pipeline by Biotron Limited, H2 2014 91 Hepatitis C - Pipeline by Bolder Biotechnology, Inc., H2 2014 92 Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H2 2014 93 Hepatitis C - Pipeline by Celgene Corporation, H2 2014 94 Hepatitis C - Pipeline by Chiasma, Inc., H2 2014 95 Hepatitis C - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 96 Hepatitis C - Pipeline by Cocrystal Pharma, Inc., H2 2014 97 Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 98 Hepatitis C - Pipeline by Conkwest, Inc., H2 2014 99 Hepatitis C - Pipeline by Crucell N.V., H2 2014 100 Hepatitis C - Pipeline by Debiopharm International S.A., H2 2014 101 Hepatitis C - Pipeline by DEKK-TEC, Inc., H2 2014 102 Hepatitis C - Pipeline by Delpor, Inc., H2 2014 103 Hepatitis C - Pipeline by Digna Biotech, S.L., H2 2014 104 Hepatitis C - Pipeline by DiscoveryBiomed, Inc., H2 2014 105 Hepatitis C - Pipeline by Eiger BioPharmaceuticals, Inc., H2 2014 106 Hepatitis C - Pipeline by Enanta Pharmaceuticals, Inc., H2 2014 107 Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 108 Hepatitis C - Pipeline by GeneCure LLC, H2 2014 109 Hepatitis C - Pipeline by Gilead Sciences, Inc., H2 2014 110 Hepatitis C - Pipeline by GlaxoSmithKline plc, H2 2014 111 Hepatitis C - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 112 Hepatitis C - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 113 Hepatitis C - Pipeline by HEC Pharm Co., Ltd., H2 2014 114 Hepatitis C - Pipeline by Hepacyl Therapeutics, SL, H2 2014 115 Hepatitis C - Pipeline by Hependo Sp. z o. o. (Ltd), H2 2014 116 Hepatitis C - Pipeline by Hetero Drugs Limited, H2 2014 117 Hepatitis C - Pipeline by Humabs BioMed SA, H2 2014 118 Hepatitis C - Pipeline by ImmunoBiology Ltd., H2 2014 119 Hepatitis C - Pipeline by Immunocore Limited, H2 2014 120 Hepatitis C - Pipeline by Immunomedics, Inc., H2 2014 121 Hepatitis C - Pipeline by Immunotech Laboratories, Inc., H2 2014 122 Hepatitis C - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 123 Hepatitis C - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 124 Hepatitis C - Pipeline by Integrated BioTherapeutics, Inc., H2 2014 125 Hepatitis C - Pipeline by iQur Ltd., H2 2014 126 Hepatitis C - Pipeline by iTherX, Inc., H2 2014 127 Hepatitis C - Pipeline by Janssen Pharmaceuticals, Inc., H2 2014 128 Hepatitis C - Pipeline by Johnson & Johnson, H2 2014 129 Hepatitis C - Pipeline by Kineta, Inc., H2 2014 130 Hepatitis C - Pipeline by Koronis Pharma, Inc., H2 2014 131 Hepatitis C - Pipeline by Lentigen Technology, Inc., H2 2014 132 Hepatitis C - Pipeline by LG Life Sciences, Ltd., H2 2014 133 Hepatitis C - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 134 Hepatitis C - Pipeline by Meda AB, H2 2014 135 Hepatitis C - Pipeline by Medivir AB, H2 2014 136 Hepatitis C - Pipeline by Merck & Co., Inc., H2 2014 137 Hepatitis C - Pipeline by Microbio Co., Ltd., H2 2014 138 Hepatitis C - Pipeline by Microbiotix, Inc., H2 2014 139 Hepatitis C - Pipeline by NasVax Ltd., H2 2014 140 Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H2 2014 141 Hepatitis C - Pipeline by New Haven Pharmaceuticals, Inc., H2 2014 142 Hepatitis C - Pipeline by Nexigen GmbH, H2 2014 143 Hepatitis C - Pipeline by Novartis AG, H2 2014 144 Hepatitis C - Pipeline by Oncolys BioPharma Inc., H2 2014 145 Hepatitis C - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 146 Hepatitis C - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 147 Hepatitis C - Pipeline by Pfenex Inc., H2 2014 148 Hepatitis C - Pipeline by Pfizer Inc., H2 2014 149 Hepatitis C - Pipeline by PharmaEssentia Corporation, H2 2014 150 Hepatitis C - Pipeline by Polaris Group, H2 2014 151 Hepatitis C - Pipeline by Presidio Pharmaceuticals, Inc., H2 2014 152 Hepatitis C - Pipeline by Profectus BioSciences, Inc., H2 2014 153 Hepatitis C - Pipeline by PTC Therapeutics, Inc., H2 2014 154 Hepatitis C - Pipeline by Quintessence Biosciences, Inc., H2 2014 155 Hepatitis C - Pipeline by Regulus Therapeutics Inc., H2 2014 156 Hepatitis C - Pipeline by RFS Pharma, LLC, H2 2014 157 Hepatitis C - Pipeline by Rodos BioTarget GmbH, H2 2014 158 Hepatitis C - Pipeline by Romark Laboratories, L.C., H2 2014 159 Hepatitis C - Pipeline by Santaris Pharma A/S, H2 2014 160 Hepatitis C - Pipeline by Scynexis, Inc., H2 2014 161 Hepatitis C - Pipeline by Seek, H2 2014 162 Hepatitis C - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 163 Hepatitis C - Pipeline by SomaGenics Inc., H2 2014 164 Hepatitis C - Pipeline by Sorrento Therapeutics, Inc., H2 2014 165 Hepatitis C - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2014 166 Hepatitis C - Pipeline by StemCells, Inc., H2 2014 167 Hepatitis C - Pipeline by Summit Corporation plc, H2 2014 168 Hepatitis C - Pipeline by Tacere Therapeutics, Inc., H2 2014 169 Hepatitis C - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2014 170 Hepatitis C - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 171 Hepatitis C - Pipeline by Therapure Biopharma Inc., H2 2014 172 Hepatitis C - Pipeline by Transgene SA, H2 2014 173 Hepatitis C - Pipeline by United Therapeutics Corporation, H2 2014 174 Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H2 2014 175 Hepatitis C - Pipeline by Vaxeal Holding SA, H2 2014 176 Hepatitis C - Pipeline by VBI Vaccines, H2 2014 177 Hepatitis C - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 178 Hepatitis C - Pipeline by ViroLogik GmbH, H2 2014 179 Hepatitis C - Pipeline by Xenetic Biosciences plc, H2 2014 180 Assessment by Monotherapy Products, H2 2014 181 Assessment by Combination Products, H2 2014 182 Number of Products by Stage and Target, H2 2014 185 Number of Products by Stage and Mechanism of Action, H2 2014 190 Number of Products by Stage and Route of Administration, H2 2014 194 Number of Products by Stage and Molecule Type, H2 2014 196 Hepatitis C Therapeutics - Recent Pipeline Updates, H2 2014 514 Hepatitis C - Dormant Projects, H2 2014 595 Hepatitis C - Discontinued Products, H2 2014 602
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
